Physician profile
Stephen D Eadline
NPI 1053303453
$1,001.21
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.17 · 2020: $62.01 · 2021: $128 · 2022: $377 · 2023: $206 · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $264.57 | 2022-2024 | Qelbree, Qelbree |
| Corium, LLC | $173.37 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $117.13 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $99.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $88.84 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $78.14 | 2019-2022 | |
| Sanofi Pasteur INC. | $63.75 | 2022-2024 | |
| Tris Pharma INC | $34.35 | 2020 | |
| Ucb, INC. | $33.66 | 2023 | Nayzilam |
| Seqirus USA INC | $18.17 | 2022 | |
| Novo Nordisk INC | $15.26 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.21 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Eadline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.